Will use Synthace's high throughput methods and tools for a number of undisclosed molecules
Synthace, a London, UK-based synthetic biology company has entered into a new relationship with MSD (known as Merck & Co in the US and Canada).
The collaboration will use Synthace’s high throughput methods and tools to develop a biomanufacturing platform for a number of undisclosed molecules. The tie-up builds on a previous agreement with MSD initiated in 2014.
'We are delighted to extend our relationship with MSD, a recognised leader in bioprocess innovation within the pharma industry,' said Tim Fell, Chief Executive of Synthace.
'This collaboration is focused on the rapid development of a high productivity, low cost of goods biomanufacturing process through the use of our next-generation approach to simultaneous genetic and process optimisation.'